SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether stereotactic body radiotherapy (SBRT)
combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) and
Thymosin Alpha 1 is safe, effective in the treatment of stage IV NSCLC patients who failed in
second-line chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University